Filing Flows › Chemours (CC) › Q2 2026 › vs Q2 2025
Chemours (CC) Q2 2026 vs Q2 2025 (year over year)
Chemours's revenue fell $24.0M (-1%) from $1.6B in Q2 2025 to $1.6B in Q2 2026. The biggest changes: All Segments −$22.0M (-1%); Other Non-Reportable Segment −$2.0M (-13%).
Chemours, Q2 2026: revenue $1.6B (-2% year over year), operating margin -0.1%, net loss $274M, operating cash flow $158M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 7.2% | 3.1% | +4.1 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| All Segments | $1.6B | $1.6B | −$22.0M | -1% |
| Other Non-Reportable Segment | $13.0M | $15.0M | −$2.0M | -13% |
| Revenue | $1.6B | $1.6B | −$24.0M | -1% |
| Net loss | $274M | $379M | −$105M | -28% |
| Costs & expenses | $1.9B | $2.0B | −$129M | -6% |
| Operating costs | $1.6B | $1.9B | −$271M | -15% |
| Income tax | $273M | $131M | $142M | +108% |
| Cost of revenue | $1.3B | $1.3B | −$32.0M | -2% |
| Operating expenses | $287M | $526M | −$239M | -45% |
| Operating cash sources | $432M | $472M | −$40.0M | -8% |
| Depreciation & amortization | $80.0M | $91.0M | −$11.0M | -12% |
| Share-based compensation | $7.0M | $7.0M | $0 | 0% |
| Working capital & other | $345M | $374M | −$29.0M | -8% |
| Net loss absorbed | $274M | $379M | −$105M | -28% |
| Operating cash flow | $158M | $93.0M | $65.0M | +70% |
| Free cash flow (OCF − capex) | $114M | $50.0M | $64.0M | +128% |
| Capital expenditures | $44.0M | $43.0M | $1.0M | +2% |
Questions
How much did Chemours's revenue grow year over year in Q2 2026?
Chemours's revenue fell $24.0M (-1%) from $1.6B in Q2 2025 to $1.6B in Q2 2026.
What drove Chemours's revenue change in Q2 2026?
All Segments −$22.0M (-1%); Other Non-Reportable Segment −$2.0M (-13%).